Increased expression of different LSC markers has been associated with poor clinical outcome in patients with AML treated with conventional chemotherapy [13], and therefore, several of those cell surface antigens might serve as therapeutic targets, such as CD123, C-type lectin-like molecule 1 (CLL-1), CD47, T cell Ig mucin 3 (TIM-3), CD96, CXCR4, or CD33 [14-20]. This evidence concerns the gene CD96 and acute myeloid leukemia.